» Articles » PMID: 7642587

Biosynthetic Processing of Neu Differentiation Factor. Glycosylation Trafficking, and Regulated Cleavage from the Cell Surface

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1995 Aug 11
PMID 7642587
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

new differentiation factor (NDF), also known as heregulin, is structurally related to the epidermal growth factor family of growth factors; it stimulates tyrosine phosphorylation of the neu/HER-2 oncogene and causes differentiation of certain human breast cancer cell lines. Alternative splicing of a single gene gives rise to multiple isoforms of NDF/heregulin, as well as the neuronal homologues, designated ARIA (acetylcholine receptor inducing activity) and GGF (glial growth factor); at least 15 structural variants are known. All but two of the NDF/heregulin cDNAs are predicted to encode transmembrane, glycosylated precursors of soluble NDF. In this report we characterized the biosynthetic processing of different NDF isoforms in stably transfected Chinese hamster ovary cells expressing individual NDF isoforms, and in the native cell line Rat 1-EJ, which expresses at least six different NDF isoforms. We found that the precursors for NDF undergo typical glycosylation and trafficking. A portion of the molecules are proteolytically cleaved intracellularly leading to the constitutive secretion of soluble, mature NDF into the culture media. However, a significant portion of the newly synthesized NDF precursor molecules escape intracellular cleavage and are transported to the cell surface of both transfected and native cells, where they reside as full-length, transmembrane proteins. Finally we show that these full-length, transmembrane NDF molecules can undergo phorbol ester regulated cleavage from the membrane, releasing the soluble growth factor into the medium.

Citing Articles

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.

Yang L, Steen T, Espinoza I, Cuyas E, Verdura S, Menendez J Am J Cancer Res. 2022; 12(5):2173-2188.

PMID: 35693067 PMC: 9185626.


Heregulin-β1 Activates NF-E2-related Factor 2 and Induces Manganese Superoxide Dismutase Expression in Human Breast Cancer Cells via Protein Kinase B and Extracellular Signal-regulated Protein Kinase Signaling Pathways.

Park J, Saeidi S, Kim E, Kim D, Na H, Keum J J Cancer Prev. 2021; 26(1):54-63.

PMID: 33842406 PMC: 8020172. DOI: 10.15430/JCP.2021.26.1.54.


Neuregulin 1: an intriguing therapeutic target for neurodevelopmental disorders.

Shi L, Bergson C Transl Psychiatry. 2020; 10(1):190.

PMID: 32546684 PMC: 7297728. DOI: 10.1038/s41398-020-00868-5.


BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia.

Zhang Z, Huang J, Shen Y, Li R Front Mol Neurosci. 2017; 10:302.

PMID: 28993723 PMC: 5622153. DOI: 10.3389/fnmol.2017.00302.


Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency.

Kim J, Casalini T, Brambilla D, Leroux J Sci Rep. 2016; 6:34297.

PMID: 27682851 PMC: 5041153. DOI: 10.1038/srep34297.